Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories Limited reports that its board approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics, Senior Management Personnel and member of the Management Council, effective July 22, 2026. An updated list of the company’s Senior Management Personnel reflects this addition.
The board also approved the appointment of Deloitte Haskins & Sells LLP as the company’s Independent Registered Public Accounting Firm to audit financial statements included in the Annual Report on Form 20-F and review interim financial statements filed on Form 6-K. This aligns with an earlier decision to appoint Deloitte Haskins & Sells LLP as statutory auditors for a term of five consecutive years from the conclusion of the 42nd AGM to the conclusion of the 47th AGM, subject to shareholder approval.
Dr. Reddy’s Laboratories Limited approved a grant of 15,933 stock options to an eligible employee under the Dr. Reddy’s Employees Stock Option Scheme, 2018. The Nomination, Governance and Compensation Committee cleared the grant by circular resolution dated July 22, 2026.
The options are Indian Stock Options with an exercise price of Rs. 1,206 per share. They provide 100% vesting at the end of 3 years and are governed by the 2018 ESOP in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Dr. Reddy’s Laboratories described a manufacturing issue in the scale‑up of the synthetic API for its semaglutide injection, where an impurity in finished product tested out of specification. The problem is confined to new scale‑up validation batches; material already supplied used a different scale, with no recalls or patient‑safety concerns identified.
Commercial supplies from the affected API facility are temporarily halted while the company investigates the root cause, adjusts the process and repeats three validation batches. Management currently expects this work, plus fill‑finish and sterility testing at partner OneSource, to run through late September, with API shipments in October and market supply resuming around late October or early November, subject to successful validation.
Because of the lost months, management now guides to 6–7 million pens of semaglutide injection in fiscal 2027, versus an earlier first‑year indication of 12 million pens. Semaglutide oral tablets, existing regulatory filings and cGMP compliance are unchanged, though batches linked to the issue at OneSource may require an inventory write‑down. The long‑term EBITDA margin goal of above 20% is reiterated.
Dr. Reddy’s Laboratories Limited will release its Q1FY27 results for the quarter ended June 30, 2026 on Wednesday, July 22, 2026, following a meeting of its Board of Directors. The results will be disseminated through stock exchanges, media, the company website, and email.
On the same day, the company’s management will host an earnings call at 19:30 PM IST / 10:00 AM ET to discuss financial performance. A press meet presentation and the audio recording and transcript of the call will be made available on the company’s website.
Dr. Reddy’s Laboratories Limited, a foreign private issuer, submitted a Form 6-K noting that an audio recording of its conference call held on July 9, 2026 is available online. The company provided a specific web link to the recording for the information and records of investors and stock exchanges.
Dr. Reddy’s Laboratories reported that certain batches of its semaglutide product were found to be out of specification due to an issue linked to the active pharmaceutical ingredient used. The company is investigating the root cause and implementing measures to protect product quality.
As a result, commercial supplies of semaglutide will be delayed for a period of time. The company stated there is no impact on patient safety or on the product’s existing global regulatory filings and emphasized its commitment to reliable global supply of this metabolic therapy. Management will host a conference call on July 9, 2026, to discuss the situation.
Dr. Reddy’s Laboratories Limited has informed shareholders about its 42nd Annual General Meeting and related shareholder communication. The AGM will be held on July 23, 2026 at 11:00 a.m. IST through video conferencing and other audio-visual means.
The company’s Notice and Integrated Annual Report for financial year 2025-26 are available online via a provided web link and QR code, and letters are being sent to shareholders without registered email addresses. The board has proposed a final dividend of ₹8 per equity share, with a record date of July 10, 2026 and payment on or before July 30, 2026.
The filing also provides e-voting details, with eligibility set by a cut-off date of July 16, 2026 and remote e-voting available from July 19 to July 22, 2026. Shareholders are requested to update their KYC details with their depository participants or the company’s registrar and transfer agent, and contact details for the registrar are provided for queries and service requests.